CoStim Pharmaceuticals is developing novel antibodies targeting immune checkpoint inhibitors for oncology indications. The company was acquired in February 2014 by Novartis (NYSE: NVS).
| Headquarters | Cambridge, MA |
| Pipeline | Preclinical at the time of acquisition |